Saturday, 27 June 2026 edition — The Vital Record
Vol. 1 · No. 25
Saturday, 27 June 2026
“Evidence earns its authority only when the record cannot be revised in the dark.”
In this edition
Today's edition leads with the simultaneous EMA revocation recommendation and FDA withdrawal proposal for avacopan — a rare dual-regulator action over alleged endpoint manipulation in the ADVOCATE trial — alongside the FDA's landmark first-line TNBC approvals for sacituzumab govitecan plus pembrolizumab, the largest Bundibugyo Ebola outbreak on record now with imported cases in Europe, and a Class I recall of the Impella heart-pump controller linked to one death.
Trials Today
Phase 4
TOPAZ (NCT03924414)
— Single-dose IV zoledronic acid vs. placebo for fracture prevention in 2,721 adults with Parkinson's disease; primary completion Feb 2026, full completion May 2026 — results not yet posted.
Phase 3
C-PRE (NCT06568172)
— NCI-sponsored trial of neoadjuvant cemiplimab in resectable stage III/IV cutaneous squamous cell carcinoma; suspended June 2026 approximately 16 months after opening — reason not specified in registry.
Phase 3
PROSPERO (NCT05742802)
— AstraZeneca's tozorakimab (anti-IL-33) extension study in 1,713 COPD patients with exacerbation history; completed May 27, 2026 at 335 global sites — results not yet posted.
Who's Who
Robert Michael
Chief Executive Officer, AbbVie
Announced AbbVie's $10.9 billion all-cash acquisition of Apogee Therapeutics on June 22, 2026, adding zumilokibart (APG777), an IL-13–targeting monoclonal antibody in late-stage development for atopic dermatitis and asthma, to AbbVie's immunology pipeline as it braces for Humira biosimilar headwinds.
The story →
The Daily Record
Medicine & biotech, fully cited, in your inbox each morning.
Free. Unsubscribe anytime.
← The archive